3 ·Filed Apr 10, 2026

ZYME

Zymeworks Inc.
NEUTRAL
Impact 3/10
Horizonweeks Processed5mo ago SEC0001193125-26-151232
Form 3 — initial insider ownership statement
Actionable Insight • Neutral

Monitor future Form 4 filings for actual transactions; the power of attorney simplifies compliance but does not indicate imminent buying or selling. Vesting schedule suggests incremental share releases starting late 2026.

DirectionNeutral
Confidencehigh
Horizonweeks
Final — all horizons settled through T+60d
ZYME ▲ +1.83% at T+60d
NEUTRAL call ✓ call won +1.83% · α vs SPY -7.09% · entry $26.17 → $26.65
Entry anchored
Apr 10, 03:59 PM ET
via exchange tick
T+1d
+3.10%
call +3.10% · α +1.89%
$26.98
settled 6mo ago
T+5d
+6.42%
call +6.42% · α +3.12%
$27.85
settled 6mo ago
T+20d
-8.18%
call -8.18% · α -15.91%
$24.03
settled 5mo ago
T+60d
+1.83%
call +1.83% · α -7.09%
$26.65
settled 3mo ago

Price Chart

Loading chart...

Executive Summary

Scott Platshon, EVP and Chief Business Officer of Zymeworks, filed a Form 3 disclosing initial beneficial ownership and granting a power of attorney to Catherine Graham and Wilson Sonsini to file required Section 16 reports on his behalf. The filing reveals no current holdings but includes previously granted stock options and RSUs.

Key Facts

  • Scott Platshon is EVP, Chief Business Officer of Zymeworks
  • Filed Form 3 to report initial beneficial ownership
  • Granted power of attorney to Catherine Graham and Wilson Sonsini attorneys to file Section 16 forms
  • Currently holds no beneficially owned securities
  • Has stock options for 167,000 shares at $22.99, granted Nov 18, 2025, vesting 25% annually
  • Has 111,111 RSUs granted Nov 18, 2025, vesting in three equal annual installments starting Nov 18, 2026

Financial Impact

No immediate financial impact; potential future dilution of approximately 0.28% of market cap ($5.6M) upon full vesting of options and RSUs

shares outstandingequity compensationdilution

Risk Factors

  • Future insider selling could create downward pressure
  • Lack of current ownership may signal misalignment with shareholders

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
3 Filing (Primary)0001193125-26-151232
Document: 0001193125-26-151232-index-headers.html0001193125-26-151232
Document: 0001193125-26-151232-index.html0001193125-26-151232
Document: 0001193125-26-151232.txt0001193125-26-151232
12 reports for ZYME
Performance horizon
88% Hit rate 7 of 8 directional calls best @ T+60▲ +16.72%Jun 14, 2026
Filters
Rows
Reports for ZYME — sortable, filterable
TypeNow
Aug 25, 2026
5w ago
8-K
BULLISH ★ 8/10
$27.47 $27.50▲ +0.11%▼ −0.87%$25.15 (−8.45%)
Jul 16, 2026
11w ago
Press Release
BEARISH ★ 6/10
$24.19 $25.76▼ −6.49%▼ −2.87%$25.15 (−3.97%)
Jun 29, 2026
13w ago
Press Release
BULLISH ★ 7/10
$24.10 $22.86▼ −5.15%▼ −4.87%$25.15 (+4.36%)
Jun 14, 2026
15w ago
Press Release
BULLISH ★ 6/10
$23.26 $24.94▲ +7.22%▲ +7.97%$25.15 (+8.13%)
May 15, 2026
20w ago
3
NEUTRAL ★ 2/10
$24.43 $22.49▼ −7.94%▼ −9.52%$25.15 (+2.95%)
Apr 21, 2026
23w ago
Press Release
BULLISH ★ 8/10
$28.53 $24.40▼ −14.48%▼ −17.64%$25.15 (−11.85%)
Apr 17, 2026
24w ago
Press Release
BULLISH ★ 7/10
$27.80 $23.96▼ −13.81%▼ −19.18%$25.15 (−9.53%)
Apr 16, 2026
24w ago
Press Release
NEUTRAL ★ 3/10
$27.20 $24.57▼ −9.67%▼ −15.48%$25.15 (−7.54%)
Apr 10, 2026
25w ago
3
NEUTRAL ★ 3/10
$26.17 $24.03▼ −8.18%▼ −15.91%$25.15 (−3.90%)
Mar 17, 2026
28w ago
Press Release
NEUTRAL ★ 3/10
$23.45 $27.20▲ +15.99%▲ +9.94%$25.15 (+7.25%)
Showing 10 of 12

US Market Status

Market Closed — Opens Mon (39h 26m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access